Auctus

Sekou Clarke Law Firm Announces Innovative Project: Business Immigration Incubator

Retrieved on: 
Tuesday, March 26, 2024
Auctus, Knowledge, Debonair, AMP, Growth, Mentorship, Incubator, Downtown Orlando, Facilitation, MBA, Investment, Tourism, Supper club, Management

One of these such groups is Sekou Clarke Law Firm and its Business Immigration Incubator program.

Key Points: 
  • One of these such groups is Sekou Clarke Law Firm and its Business Immigration Incubator program.
  • The Business Immigration Incubator emerged from a visionary initiative by Sekou Clarke Law Group and Auctus Marketing Partners to address the unique challenges faced by immigrant entrepreneurs.
  • Creating the incubator was a result of the beautiful marriage of the Sekou Clarke's Law Group expertise and their passion in the immigration space.
  • The Business Immigration Incubator is led by the mind of Sekou Clarke.

Auto Parts 4 Less Group Inc. Announces Major Debt Restructuring and Continuation of Growth Strategy

Retrieved on: 
Tuesday, February 20, 2024
Auctus, OTC, O'Reilly Auto Parts, FLES, D2C, Security (finance)

The company has entered into agreements with Auctus Investment Group and Growth Ventures to convert a combined total of $7,439,599 of outstanding debt into a preferred share structure.

Key Points: 
  • The company has entered into agreements with Auctus Investment Group and Growth Ventures to convert a combined total of $7,439,599 of outstanding debt into a preferred share structure.
  • This strategic move is expected to enhance the company's balance sheet and provide greater financial flexibility.
  • Christopher Davenport, CEO of Auto Parts 4 Less Group Inc., stated: "We are thrilled to announce this significant milestone in our ongoing efforts to strengthen our financial position.
  • For more information about Auto Parts 4 Less Group Inc., please visit www.AutoParts4LessGroup.com

Intelligent Bio Solutions Inc. Reports Fiscal Second Quarter and Six-Month Financial Results and Operational Highlights

Retrieved on: 
Friday, February 9, 2024
Titan, Auctus, P&O Ferries, Accreditation, Acquisition, Growth, Intelligence, Safety, National Association, Risk, RASL, NATA, Cryptocurrency

NEW YORK, Feb. 09, 2024 (GLOBE NEWSWIRE) --  Intelligent Bio Solutions Inc. ("INBS" or the "Company") (Nasdaq: INBS), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced its financial results for fiscal second quarter and six months ended December 31, 2023, and provided a business update.

Key Points: 
  • “We are very pleased with our fiscal Q2 and six-month revenue results, reflecting our commitment to continuous growth of our customer base and global presence,” said, Harry Simeonidis, President and Chief Executive Officer at Intelligent Bio Solutions.
  • Last year our expansion into New Zealand marked a significant milestone, and we anticipate further expansion throughout the Asia-Pacific region this year.
  • The National Association of Testing Authorities (NATA) accredited Intelligent Bio Solutions’ laboratory partner, Racing Analytical Services Limited (RASL), to perform its fingerprint confirmatory drug testing procedure.
  • Fiscal Second Quarter Ended December 31, 2023, Financial Results
    All amounts are expressed in U.S. dollars unless indicated otherwise.

Fingerprint Drug Test Delivers Quantifiable Benefits for Customers as Adoption in Workplaces Accelerates

Retrieved on: 
Tuesday, January 30, 2024
Well, Auctus, Intelligence, DGP, Overalls, P&O Ferries, Urine, Workplace, HR, Organization, Medical device

NEW YORK, Jan. 30, 2024 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) (“INBS” or the “Company”), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today reported on the key operational benefits that customers are experiencing following deployment of the Intelligent Fingerprinting Drug Screening System to support workplace drug testing.

Key Points: 
  • “We’re seeing an increasing need for drug and alcohol testing across major construction and manufacturing projects.
  • Well-supported employee inductions on one of Europe’s largest construction sites: Auctus Management Group has implemented a streamlined induction process utilizing the Intelligent Fingerprinting Drug Screening System at its core.
  • DGP has effectively minimized on-site disruption caused by half-day absences required for urine-based testing by switching to quick, on-site fingerprint sweat-based drug screening in minutes.
  • Achieved greater control through in-house management of drug testing: Independent chemical manufacturer Robinson Brothers found that replacing its external urine-based drug testing service with the Intelligent Fingerprinting Drug Screening System meant it could conduct the same volume of workplace drug screening at around half the cost.

Intelligent Bio Solutions Inc. Reports Fiscal 2024 First Quarter Financial Results and Operational Highlights

Retrieved on: 
Wednesday, November 8, 2023
Auctus, FDA, Ketamine, Mining, Government, Acquisition, Aviation, Growth, Agriculture, Tramadol, ISO, Intelligence, Cryptocurrency, Pharmaceutical industry

NEW YORK, Nov. 08, 2023 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. ("INBS" or the "Company") (Nasdaq: INBS), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced its financial results for its fiscal first quarter ended September 30, 2023, and provided a business update.

Key Points: 
  • First Quarter & Recent Highlights:
    Expanded into the New Zealand market, representing a significant milestone in the Company’s growth strategy for its Intelligent Fingerprinting Drug Screening System.
  • Enhanced customer portfolio with specialist container logistics firm VKVP Haulage adopting the Company’s Intelligent Fingerprinting Drug Screening System.
  • Additionally, existing customer Auctus Management Group completed 25,000 tests using the Company’s Intelligent Fingerprinting Drug Screening System.
  • First Fiscal Quarter Ended September 30, 2023, Financial Results
    All amounts are expressed in U.S. dollars unless indicated otherwise.

Intelligent Bio Solutions Adds Logistics Firm to Fingerprint Drug Screening Portfolio and Completes Major Milestone with Existing Client

Retrieved on: 
Thursday, October 5, 2023
Auctus, Health, Urine, Non-intrusive stress measurement system, Transport, Safety, Workforce, Policy, Hygiene, Intelligence, HGV, Medical device

NEW YORK, Oct. 05, 2023 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) (“INBS” or the “Company”), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced the adoption of its Intelligent Fingerprinting Drug Screening System by specialist container logistics firm, VKVP Haulage. Additionally, the Company announced the successful completion of 25,000 Intelligent Fingerprinting tests with its current customer, Auctus Management Group.

Key Points: 
  • NEW YORK, Oct. 05, 2023 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) (“INBS” or the “Company”), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced the adoption of its Intelligent Fingerprinting Drug Screening System by specialist container logistics firm, VKVP Haulage .
  • Additionally, the Company announced the successful completion of 25,000 Intelligent Fingerprinting tests with its current customer, Auctus Management Group .
  • “The Intelligent Fingerprinting Drug Screening System is a great testing solution we can use in-house as needed.
  • The use of our Intelligent Fingerprinting Drug Screening System by Auctus Management Group is a great example of the convenience and efficiency of our Intelligent Fingerprinting solution and demonstrates how our technology can deliver drug testing at scale.”
    An introductory video demonstrating the Intelligent Fingerprinting Drug Screening System is available here.

ID.me Appoints Samantha Greenberg as Chief Financial Officer and Raises $132 Million in Series D Funding

Retrieved on: 
Tuesday, April 11, 2023
Auctus, Citadel, Treasury, Bloomberg Businessweek, Stanford University, Identity theft, Postgraduate education, Business, MBA, ID.me, Allianz Global Investors, Goldman Sachs, CNBC, M&A, Wharton School of the University of Pennsylvania, Stanford Graduate School of Business, Ernst & Young, Stanford University centers and institutes, Paulson, CapitalG, Commerce, Widener University Commonwealth Law School, Growth, CFO, Joseph M. Katz Graduate School of Business, Government, Institutional investor, Woman, Conference, Viking Global Investors, Economics, Institutional Investor, Cryptocurrency

MCLEAN, Va., April 11, 2023 /PRNewswire/ -- ID.me, the secure digital identity network with more than 100 million members , announced today the appointment of Samantha Greenberg as Chief Financial Officer.

Key Points: 
  • MCLEAN, Va., April 11, 2023 /PRNewswire/ -- ID.me, the secure digital identity network with more than 100 million members , announced today the appointment of Samantha Greenberg as Chief Financial Officer.
  • Greenberg brings to ID.me over 20 years of experience leading financial operations, analyzing private and public technology and consumer companies, and scaling high-growth businesses.
  • The latest round brings the total investment in the company to more than $240 million since its founding in 2010.
  • Samantha is joining our team at the right time, after we closed our Series D funding and surpassed 100 million members.

Syntekabio Inc.: 2023 Trends in New Drug Development

Retrieved on: 
Thursday, February 2, 2023
Auctus, Q&A, PGM, NGS, EVP, Scientific Integrity in Policymaking, JD, Columbia University, Artificial intelligence, Legislation, STB, Drug discovery, Science, Doctor of Philosophy, COVID-19, Pharmaceutical industry, MD

The webinar features panelists from Columbia University, Janssen, Syntekabio (KOSDAQ:226330.KQ) and Auctus Capital

Key Points: 
  • The webinar features panelists from Columbia University, Janssen, Syntekabio (KOSDAQ:226330.KQ) and Auctus Capital
    Syntekabio (KOSDAQ:226330.KQ)(226330:KS), a global AI drug discovery and development company, will participate in a special webinar hosted by the New York Health Forum (NYHF) on the latest drug discovery and development trends.
  • What is at the core of transforming a once lengthy process full of complexity and uncertainties?
  • Advancements in new technologies, including artificial intelligence (AI), Covid-19 and drug pricing legislation have disrupted drug discovery and development in the global biopharma industry.
  • Syntekabio is leading this industry-wide transformation with its latest invention STB CLOUD, which can give clinical-stage pharmaceutical companies with limited drug discovery capability an ideal one-stop solution for fully automatic drug discovery.

Guided Therapeutics Closes $3.3 Million Bridge Financing

Retrieved on: 
Wednesday, September 7, 2022
Oncology, Health, FDA, Medical Devices, Other Science, Science, Biotechnology, Auctus, IRB, CEO, Technology, Therapy, File, Disease, Sale, Cervical cancer, Biophotonics, SEC, Goal, Company, FDA, News, LLC, Stock dilution, Risk, Annual report, Woman, OTCQB, Trial of the century, Security (finance), Pharmaceutical industry, Risk management, Medical imaging, Nasdaq, Gemstar–TV Guide International, Cocceius Auctus

Guided Therapeutics, Inc. or the Company (OTCQB: GTHP), the maker of a rapid and painless testing platform based on its patented biophotonic technology, announced today that it had raised approximately $3.3 million through the sale of 6.6 million shares of the Companys common stock at 50 cents each.

Key Points: 
  • Guided Therapeutics, Inc. or the Company (OTCQB: GTHP), the maker of a rapid and painless testing platform based on its patented biophotonic technology, announced today that it had raised approximately $3.3 million through the sale of 6.6 million shares of the Companys common stock at 50 cents each.
  • To this point, this bridge financing has brought the Companys stockholders equity to nearly break even, assuming current existing exchange agreements are implemented.
  • said Gene Cartwright, CEO of Guided Therapeutics.
  • The Guided Therapeutics LuViva Advanced Cervical Scan is an investigational device and is limited by federal law to investigational use in the U.S. LuViva, the wave logo and "Early detection, better outcomes" are registered trademarks owned by Guided Therapeutics, Inc.

Margie Thomas Joins Auctus Search Partners, LLC

Retrieved on: 
Wednesday, June 1, 2022
Auctus, Marketing, Technical support, Cisco Systems, Software engineer, LLC, Portfolio company, Investment banking, Multimedia, Recruitment, Magic Circle (law firms), Country, Hewlett-Packard, Golf, Margie, Customer success, Digital marketing, Technology, Employment agency, Veritas

CHICAGO and DENVER and SILICON VALLEY, Calif., June 1, 2022 /PRNewswire/ -- Auctus Search Partners, LLC is excited to announce Margie Thomas has joined the firm as a Managing Director and Executive Recruiter.

Key Points: 
  • CHICAGO and DENVER and SILICON VALLEY, Calif., June 1, 2022 /PRNewswire/ -- Auctus Search Partners, LLC is excited to announce Margie Thomas has joined the firm as a Managing Director and Executive Recruiter.
  • Margie Thomas Joins Auctus Search Partners, LLC Expands Auctus Search Partners Capabilities to Recruit all Tech roles
    Executive Recruitment: Technology executive recruitment of all job roles within the technology sector including but not limited to Digital Marketing, Software Sales and Customer Success, IoT Product Management and IT Support.
  • Most recently, Margie has successfully leveraged her business experience into Executive Recruitment, placing key executives across corporations within the technology sector.
  • Auctus Search Partners, LLC is a recruitment consultancy firm focused on recruiting, consulting and placing top-tier talent into Investment Banks, Private Equity Firms and their Portfolio Companies.